Check for updates

CORRESPONDENCE **OPEN** Genetically determined telomere length and risk for haematologic diseases: results from large prospective cohorts and Mendelian Randomization analysis

© The Author(s) 2024

Blood Cancer Journal (2024)14:48; https://doi.org/ 10.1038/s41408-024-01035-5

TO THE EDITOR:

Telomere attrition and epigenetic modifications stand out as prominent molecular characteristics of aging-related biological processes and important risk factors for the development of haematologic diseases [1]. The relationship between telomere length and the risk of haematologic diseases has been extensively studied. However, the results of these studies have been conflicting [2]. The predictions of epigenetic clocks often deviate from chronological age, leading to a phenomenon known as epigenetic age acceleration (EAA) [3]. Empirical observations indicate that EAA is linked to an elevated risk of several health conditions [4]. However, this phenomenon has yet to be systematically evaluated for haematologic diseases. The objective of our study was to conduct a Mendelian randomization (MR) investigation, utilizing germline genetic variants as instrumental variables for both telomere length and EAA, to explore whether telomere length and EAA are associated with an increased risk of various haematologic diseases, including anaemia, lymphoma, leukaemia, myeloproliferative diseases, haemostasis and coagulation diseases, and other haematological disorders.

We initially conducted a two-sample single-variable MR (SVMR) study. This was then followed by verification using a validation dataset and different MR methods with different model assumptions. A series of multivariable MR (MVMR) analyses were then conducted to adjust for statistically significant risk factors. Furthermore, MVMR analysis based on Bayesian model averaging (MVMR-BMA) was performed to rank the aforementioned aging factors based on genetic evidence and assess whether telomere attrition, even in the presence of epigenetic aging, remains the true causal factor for haematologic diseases. Figure 1A presents an overview of the study design.

For telomere length analysis, data sources were derived from the UK Biobank, a comprehensive population-based cohort study comprising 472,174 participants [5]. To conduct SVMR analyses, we followed a rigorous selection process to derive a final set of 121 instrumental variables (Supplementary Tables 1 and 2). For epigenetic age acceleration measures, we acquired summary genetic association estimates from a recent GWAS meta-analysis of biological aging [6]. In certain cases, several SNPs were eliminated to address potential pleiotropic outliers. Specifically, we identified four independent SNPs for GrimAge, seven for HannumAge, 22 for Intrinsic HorvathAge, four for DNAm PAI-1 and 10 for PhenoAge (Supplementary Tables 3-8). Summary-level genetic association data for multiple haematologic disease outcomes were acquired from several sources (Table 1). In the discovery cohort, we obtained an extensive set of 59 GWASs from FinnGen [7]. Supplementary Fig. 1 demonstrates which specific haematologic diseases constitute each of the 59 GWAS summary statistic. In the validation cohort, GWAS data were sourced from both the UK Biobank cohort and several international consortia. In the MVMR analysis, we incorporated all the risk factors identified from the SVMR analysis, with a particular focus on assessing the significance of telomere length. To satisfy the instrumental SNP independence requirement in the MVMR-BMA, LD clumping was applied to the combination of SNPs of all aging risk factors. The detailed process of statistical analysis was provided in the Supplementary Method.

The SVMR results between genetically determined telomere length and haematologic diseases are presented in Fig. 1B. Genetically increased telomere length was associated with higher ORs (95% Cls) of disease in 10 of the 21 haematological malignancies (P < 0.05) (Supplementary Fig. 3). Associations (IVW ORs; [95% CIs] per 1-SD change in genetically increased telomere length; P-value) were observed: lymphoid leukaemia (2.4249; [1.4933-3.9377]; 0.0003), acute lymphocytic leukaemia (2.8931; [1.2466-6.7145]; 0.0134), chronic lymphocytic leukaemia (2.1969; [1.0122-4.7681]; 0.0465), essential thrombocythaemia (2.1647; [1.1774-3.9799]; 0.0129), malignant immunoproliferative diseases (3.7905; [1.3200-10.8853]; 0.0133), Hodgkin lymphoma (2.2305; [1.2354-4.0273]; 0.0078), non-Hodgkin lymphoma (1.7558; [1.1604–2.6567]; 0.0077), non-follicular lymphoma (1.4877; [1.0816-2.0463]; 0.0146), other and unspecified types of non-Hodgkin lymphoma (1.7887; [1.0840-2.9515]; 0.0229) and multiple myeloma and malignant plasma cell neoplasms (1.6458; [1.0328-2.6225]; 0.0361) (Fig. 1B). These significant results were successfully replicated in an independent validation cohort. (Supplementary Fig. 2a).

Utilizing a meta-analysis of IVW SVMR, we found no evidence of genetically predicted DNA methylation GrimAge acceleration associated with the risk of the mentioned haematologic diseases. Causal estimation showed that genetically determined Hannum age acceleration was associated with a lower risk of developing chronic myeloid leukaemia (OR = 0.5553 per year increase in Hannum age acceleration, 95% CI 0.3182-0.9690, P value = 0.0384). Our findings showed no evidence of causality between genetically predicted Intrinsic EAA and the aforementioned haematologic disorders. Genetically predicted higher levels of DNAm PAI-1 exhibited marginally significant causal associations with an increased risk of chronic myeloid leukaemia. We also

Received: 15 January 2024 Revised: 29 February 2024 Accepted: 7 March 2024 Published online: 18 March 2024

С

	2	
	,	
1	-	

A

(a) Univariable MR to identify the

(b) Multivariable MR to evaluate if

nstrumental variable

В

causal associ	intion betw	een telo	mere attri	ion and enigen	etic aging and					
haema	tologic dis	eases	mere atar	ion and epigen	ene uging unu	Outcome	Exposure	P-value		OR(95%CI)
			_		-	Discovery cohort				
			-7 C	onfounders		Lymphoid leukaemia	Telomere length	0.0001		2.8979(1.7986-4.6739)
		********		~	_		GrimAge acceleration	0.539	+	1.0865(0.8328-1.4191)
ssumption			/				Hannum age acceleration	0.262	-	1.1241(0.9167-1.3785)
			/				Intrinsic epigenetic age acceleration	0.161	-	0.9012(0.7788-1.0429)
-		/					DNAm PAI-1	0.749	÷	1(1-1)
	Exposi	ire		1			PhenoAge acceleration	0.637	+	1.0398(0.8851-1.2202)
	Telomere I	ength				Chronic lymphocytic leukaemia	Telomere length	0.001		3.7848(1.77-8.1011)
Gri	imAge acc	eleration			Outcome		GrimAge acceleration	0.917	-	0 9773(0 6402-1 4933)
Han	num age ac	celeratio	on		Haematologic diseas	s	Hannum age acceleration	0.121	in the second se	1 203(0 0352-1 7878)
Intrinsic e	pigenetic a	ige acce	leration	L	5		Intrinsis epigenetic age acceleration	0.059	10	0.7003/0.6344 1.009)
Phe	DIVAIN F	eleration	n				Intrinsic epigenetic age acceleration	0.050	-1	0.7885(0.0344-1.000)
				-			DINAM PAI-1	0.958	1.	1(1-1.001)
	X						PhenoAge acceleration	0.062	-	1.2751(0.9681-1.6454)
Exclusion	n restriction	on assu	mption			Myeloid leukaemia	Telomere length	0.404		1.3896(0.6415-3.0072)
							GrimAge acceleration	0.449		1.1806(0.7672-1.8167)
							Hannum age acceleration	0.292	-	0.8378(0.6029-1.1642)
							Intrinsic epigenetic age acceleration	0.454	+	1.0942(0.865-1.384)
alonara attrii	ition manai		l aisen atl	ar anicanatio o	aina siek featam		DNAm PAI-1	0.328	- †	1(1-1.001)
cromere auti	nion remai	na cuusu	i given ou	ier epigenette a	iging risk factors		PhenoAge acceleration	0.826	+	0.9714(0.7498-1.2586)
						Chronic myeloid leukaemia	Telomere length	0.666		1.2815(0.4152-3.959)
Tel	omere leng	gth			Confounders		GrimAge acceleration	0.198		1.5129(0.8057-2.8377)
		_	and the second	< /			Hannum age acceleration	0.199		0.7291(0.4507-1.1806)
Grim		ntion		1			Intrinsic epigenetic age acceleration	0.625		1.0898(0.7726-1.5373)
Grintz	ige accerei	auton		1			DNAm PAI-1	0.107	÷	1.001(1-1.001)
			1	*	Outcome		PhenoAge acceleration	0.25		0.8001(0.5477-1.17)
	:		1		Haematologic diseas	S Multiple myeloma and malignant plasma cell neoplasms	Telomere length	0.113		1.4579(0.9148-2.3233)
				×			GrimAge acceleration	0.404	-	1.1174(0.8607-1.4506)
Pheno	Age accele	ration]	Hannum age acceleration	0.699	+	1.0398/0.8521-1.27)
							Intrinsic epigenetic age acceleration	0.434	1	1.0587(0.0495.1.2202)
								0.431	T	1.0001(0.8103-1.2202)
							DNAm PAI-1	0.856	1	1(1-1)
							PhenoAge acceleration	0.764	1	0.9763(0.8344-1.1422)
						Acute lymphocytic leukaemia	Telomere length	0.009		→ 3.0557(1.3245-7.0498)
	nSNP	P-value		5	OR(95%CI)		GrimAge acceleration	0.516		1.1665(0.7327-1.8552)
very cohort							Hannum age acceleration	0.531	+	0.8932(0.6275-1.2712)
Anaemias	121	0.9747	+	1	1.0025(0.8609-1.1673)		Intrinsic epigenetic age acceleration	0.197	- -	0.8454(0.6551-1.0909)
l anaemias	121	0.4391		1	1.0542(0.9223-1.2049)		DNAm PAI-1	0.625	- ÷	1(0.999-1)
v anaemia	121	0.1173	- i-		1 127(0 9704-1 3088)		PhenoAge acceleration	0.732	+	1.0502(0.7929-1.391)
s (chronic)	121	0.8344	4		0.975(0.769-1.2362)	Essential thrombocythaemia	Telomere length	0.019		2.335(1.1468-4.7541)
deficiency	121	0.0372	4		2044(1.0111-1.4348)		GrimAge acceleration	0.682	+	1.0865(0.7305-1.6161)
v anaemia	121	0.0782			7656(0 5687-1 0306)		Hannum age acceleration	0.562	-	1 0942(0 8073-1 4829)
Lanaemias	121	0.4374	1.	_	1 4486(0 5685-3 691)		Intrinsic enigenetic age acceleration	0.258	<u> </u>	1 1331(0 9121-1 4078)
anaomias	121	0.9505	1		0996(0 5494 1 7921)		Dhiam Bal 1	0.24	1	10 000 1)
anaemias	121	0.9095	T		1.9000(0.0404-1.7021)		DNAM PAI-1	0.34	1	1(0.999-1)
ic anaernia	121	0.9955	- T		1.0021(0.4740-2.110)		PhenoAge acceleration	0.719	T	0.957(0.7535-1.2153)
anaemias	121	0.8586	-		3.9086(0.3164-2.6093)	Malignant immunoproliferative diseases	Telomere length	0.041		→ 3.0012(1.045-8.6279)
anaemias	118	0.7513	1	- 1	1.1943(0.3984-3.5804)		GrimAge acceleration	0.554	-	0.8369(0.4644-1.5098)
r anaemias	121	0.2667		0	0.9214(0.7975-1.0646)		Hannum age acceleration	0.623	-	0.8932(0.5689-1.4021)
anaemias	121	0.7674	+		1.1576(0.439-3.0522)		Intrinsic epigenetic age acceleration	0.942	+	1.0121(0.7334-1.3965)
ic anaemia	121	0.7069	+		0.902(0.5269-1.5441)		DNAm PAI-1	0.941	÷	1(0.999-1.001)
elsewhere	121	0.3285		- 1	1.5077(0.6617-3.4354)		PhenoAge acceleration	0.203		1.2586(0.8834-1.795)
r anaemias	121	0.159	- H		0.897(0.7712-1.0435)	Hodgkin lymphoma	Telomere length	0.018		2.0381(1.1286-3.684)
i anaemias	121	0.2281	1		0.9111(0.7831-1.06)		GrimAge acceleration	0.461	4	1 132(0 8138-1 5762)
ion defects	121	0.4826	-		1.299(0.6258-2.6963)		Henry and acceleration	0.957	1	0.0772/0.7598 1.2572)
nd disease	120	0.5359		1	1.4208(0.4673-4.3194)		Hannum age acceleration	0.007	T	0.8773(0.7388-1.2373)
ting factors	121	0.7443	÷		1.205(0.393-3.6945)		Intrinsic epigenetic age acceleration	0.824	T	1.0212(0.8521-1.2226)
conditions	121	0.3991	4		0.903(0.7122-1.1448)		DNAm PAI-1	0.329	1	1(1-1.001)
ion defects	121	0.5266	+	1	1.1424(0.7566-1.7248)		PhenoAge acceleration	0.579	- T	1.0576(0.8668-1.2905)
coagulants	121	0.0913		0	0.4086(0.1446-1.1547)	Non-follicular lymphoma	Telomere length	0.014		1.4903(1.0833-2.0503)
ion defects	121	0.3027	-	1	1.3108(0.7834-2.1932)		GrimAge acceleration	0.374	+	1.0844(0.9066-1.2956)
conditions	121	0.1655	4		0.8202(0.6199-1.0853)		Hannum age acceleration	0.452		0.9493(0.8278-1.0876)
pic purpura	121	0.7843	+		0.9299(0.5528-1.5644)		Intrinsic epigenetic age acceleration	0.925	+	1.005(0.9112-1.1074)
nic purpura	121	0.0634		(0.2982(0.0831-1.0697)		DNAm PAI-1	0.567	÷	1(1-1)
nic purpura	121	0.7811	+		0.9196(0.509-1.6612)		PhenoAge acceleration	0.845	+	1.0111(0.9076-1.1252)
ocytopenia	121	0.4819	-	(0.6588(0.2059-2 1079)	Other and unspecified types of non-Hodgkin lymphoma	Telomere length	0.018		1.8984(1.1174-3.2252)
ocytopenia	121	0.134	-		0.7133(0.4584-1.1097)		GrimAge acceleration	0.695	+	0.9427(0.7012-1.2674)
conditione	121	0,4534	-		9173(0 3774-2 2204)		Hannum age acceleration	0.929	+	0.99(0.789-1.2411)
leukaemia	120	0.0003	1	_	2 4249(1 4933-3 9377)		Intrinsic epigenetic age acceleration	0.995	4	0.999(0.8504-1.1747)
leukaemia	120	0.0134			2 8931(1 2466-6 7145)		DNAm PAL-1	0.803	4	1(1-1)
leukaemia	110	0.0465	-		2 1969(1.0122-4 7684)		PhenoAre acceleration	0.638	+	1.0439(0 8737-1 2473)
leukaemia	124	0.4827	-		1 3131/0 6138-2 8090)	Non-Hodakin lumnhoma	Telomera longth	0.032		1 5652/1 0377-2 2609
leukaemia	121	0.1996	1		3257(0 6404.8 4466)	Non-noughin lymphoma	GrimAge acceleration	0.035	1	1.0101/0.8040-1.071
leukaemia	121	0.5224	1		4424(0 4695 4 4313)		GrimAge acceleration	0.925	T	0.0714/0.0171 1.0127)
ad cell time	121	0.1160	1		6397(0 7864 9 960**		mannum age acceleration	0.741	I	0.9714(0.8171-1.1549)
e disearce	121	0.0757	-		1.5368/0.9565-2.4604		ministic epigenetic age acceleration	0.721	I	1.0233(0.903-1.1595)
a anacuatta	110	0.3407	1		4973/0 7663-2 9565		DNAm PAI-1	0.63	1	1(1-1)
andirector	119	0.2407	-		6183(0 1012 1 0005)		PhenoAge acceleration	0.976	1	0.998(0.8694-1.1445)
we disease	118	0.422	1	(.0105(U.1912-1.9993)	Other and unspecified iron deficiency	Telomere length	0.156	*	1.1354(0.9531-1.3526)
ocythaemia	118	0.0129	-	- 3	0.645/0.0780 1.00199)		GrimAge acceleration	0.52	- T	1.0325(0.9361-1.1388)
ease (BM)	121	0.3054	T	-	0.045(0.2789-1.4918)		Hannum age acceleration	0.497	+	1.0263(0.9522-1.1063)
e diseases	121	0.0133	1	• • •	3.7905(1.32-10.8853)		Intrinsic epigenetic age acceleration	0.517	÷	1.0182(0.9646-1.0736)
rymphoma	121	0.448	1	2	1.3602(0.6004-3.173)		DNAm PAI-1	0.998	+	1(1-1)
lymphoma	121	0.4521	+		0.8191(0.487-1.3779)		PhenoAge acceleration	0.013	4	0.9287(0.8755-0.9841)
lymphoma	121	0.0078	-	- 2	2.2305(1.2354-4.0273)	Other disorders of white blood cells	Telomere length	0.263	+	0.7765(0.4986-1.2092)
ymphomas	121	0.0563	•		0.3959(0.1529-1.025)		GrimAne acceleration	0 744	+	0.9598/0 749-1 2289
lymphoma	121	0.0146	100	1	1.4877(1.0816-2.0463)		Hannum are acceleration	0.228	-	1 1241/0 9295-1 359
lymphoma	121	0.0229	-		1.7887(1.084-2.9515)		Internation age acceleration	0.220	1	0.025/0.8092.4.0507
lymphoma	120	0.0077	-	1	1.7558(1.1604-2.6567)		mumsic epigenetic age acceleration	0.258	1	0.925(0.8082-1.0587)
neoplasms	121	0.0361		1	1.6458(1.0328-2.6225)		DNAm PAI-1	0.693	T.	1(1-1)
onucleosis	121	0.8925	+	1	1.0227(0.7385-1.4162)		PhenoAge acceleration	0.907	1	1.009(0.8694-1.1712)
myloidosis	121	0.7393	+	1	1.1257(0.5604-2.2614)	Other and unspecified coagulation defects	Telomere length	0.119		1.4948(0.9021-2.4744)
nulocytosis	121	0.8569	+	c	0.9736(0.7282-1.3017)		GrimAge acceleration	0.866	+	1.0243(0.7726-1.358)
eutropenia	121	0.5526	+		1.1214(0.7683-1.6367)		Hannum age acceleration	0.413	-	1.0942(0.8816-1.358)
osinophilia	121	0.3281	-		0.6584(0.2849-1.5216)		Intrinsic epigenetic age acceleration	0.516	+	0.9503(0.8146-1.1085)
blood cells	121	0.3372	+		0.7744(0.4595-1.3053)		DNAm PAI-1	0.792	4	1(1-1)
blood cells	121	0.1844	4		7409(0 4759-1 1534)		PhenoAge acceleration	0.207	4	0.8967(0.7565-1.0618)
	141	0.1041	-		(0.1100 1.1004)			5	1	

Fig. 1 Study design and Mendelian randomization results. A Study design (a) The causal diagram illustrating the standard Mendelian randomization (MR) analysis with instrumental variables (IV) and the three necessary assumptions. (b) An illustrative diagram demonstrating the IV assumptions utilized in the multivariable MR model. **B** Two-sample single-variable Mendelian randomization results of telomere length on risk of multiple haematologic diseases in the discovery cohort. **C** Multivariable Mendelian randomization results of telomere length and five epigenetic age acceleration on risk of multiple haematologic diseases in the discovery cohort. **C** Multivariable Mendelian randomization; IV, instrumental variable; DNAm PAI-1, DNA methylation-estimated plasminogen activator inhibitor-1; nSNP, number of single nucleotide polymorphism; OR, odds ratio; 95% CI, The 95% confidence intervals.

found that higher PhenoAge acceleration was associated with increased risks of myeloid leukaemia (OR = 1.3018 per year increase in PhenoAge acceleration, 95% CI 1.0596–1.5994, *P* value = 0.0120), chronic lymphocytic leukaemia (OR = 1.2280, 95% CI 1.0118–1.4905, *P* value = 0.0376), and lymphoid leukaemia (OR = 1.1539, 95% CI 1.0267–1.2968, *P* value = 0.0163) (Supplementary Fig. 2b–f). The causal analysis of genetically determined 5

EAA in an independent validation cohort yielded similar results (Supplementary Fig. 4). The consistency of these above SVMR results was further supported by other MR methods, and no heterogeneity and horizontal pleiotropy were detected (Supplementary Tables 9 and 10).

Subsequently, our focus shifted to statistically significant haematological disorders identified through SVMR analysis. We conducted

Variable	Source	Cases	Controls	Sample size
Exopsure				
Telomere length	UK Biobank data	472,174	/	472,174
DNAm GrimAge acceleration	PMID: 34187551	34,467	/	34,467
DNAm Hannum age acceleration	PMID: 34187551	34,449	/	34,449
Intrinsic epigenetic age acceleration	PMID: 34187551	34,461	/	34,461
DNAm PAI-1	PMID: 34187551	34,448	/	34,448
DNAm PhenoAge acceleration	PMID: 34187551	34,463	/	34,463
Outcome of discovery cohort				
Anaemias	FinnGen data D3_ANAEMIA	27,371	88,536	115,907
Nutritional anaemias	FinnGen data D3_NUTRIANAEMIA	7677	211,115	218,792
Iron deficiency anaemia	FinnGen data D3_ANAEMIA_IRONDEF	13,689	360,528	374,217
Iron deficiency anaemia secondary to blood loss (chronic)	FinnGen data D3_ANAEMIA_IRONDEF_BLOODLOSS	4852	360,528	365,380
Other and unspecified iron deficiency	FinnGen data D3_ANAEMIA_IRONDEF_NAS	10,208	360,528	370,736
Vitamin B12 deficiency anaemia	FinnGen data D3_ANAEMIA_B12_DEF	3351	360,528	363,879
Other nutritional anaemia	FinnGen data D3_NUTRIANAEMIAOTHER	283	360,528	360,811
Haemolytic anaemias	FinnGen data D3_HAEMOLYTICANAEMIA	838	376,439	377,277
Acquired haemolytic anaemia	FinnGen data D3_ACQHAEMOLYTICANAEMIA	606	376,439	377,045
Other autoimmune haemolytic anaemias	FinnGen data D3_AIHA_OTHER	280	376,439	376,719
Other and unspecified acquired haemolytic anaemias	FinnGen data D3_ACQHAEMOLYTICANAEMIANAS	241	376,439	376,680
Aplastic and other anaemias	FinnGen data D3_APLASTICANDOTHANAEMIA	6554	212,238	218,792
Other and unspecified aplastic anaemias	FinnGen data D3_OTHERAPLASTICANAEMIA	288	362,319	362,607
Acute posthaemorrhagic anaemia	FinnGen data D3_ACUTEPOSTBLEEDANAEMIA	976	362,319	363,295
Anaemia in chronic diseases classified elsewhere	FinnGen data D3_ANAEMIAINCHRONICDISEASE	585	362,319	362,904
Other anaemias	FinnGen data D3_OTHERANAEMIA	6005	212,238	218,243
Other and unspecified anaemias	FinnGen data D3_ANAEMIANAS	13,600	362,319	375,919
Chronic Coagulation defects	FinnGen data D3_COAGDEF	626	376,651	377,277
Von Willebrand disease	FinnGen data D3_VONVILLEBRAND	336	371,504	371,840
Hereditary deficiency of other clotting factors	FinnGen data D3_HEREDOTHCLOFACTORS	216	371,504	371,720
Coagulation defects, purpura and other haemorrhagic conditions	FinnGen data D3_COAGDEF_PURPUR_HAEMORRHAGIC	5773	371,504	377,277
Other coagulation defects	FinnGen data D3_COAGOTHER	1904	371,504	373,408
Haemorrhagic disorder due to circulating anticoagulants	FinnGen data D3_HAEMORRHAGCIRGUANTICO	267	371,504	371,771
Other and unspecified coagulation defects	FinnGen data D3_COAGDEFNAS	1217	371,504	372,721
Purpura and other haemorrhagic conditions	FinnGen data D3_PURPURA_AND3_OTHER_HAEMORRHAGIC	3900	371,504	375,404
Allergic purpura	FinnGen data D3_ALLERGPURPURA	856	371,504	372,360
Other nonthrombocytopenic purpura	FinnGen data D3_OTHNONTHROMBOCYTOPENPURPURA	214	371,504	371,718
ldiopathic thrombocytopenic purpura	FinnGen data D3_ITP	810	371,504	372,314
Secondary thrombocytopenia	FinnGen data D3_SCNDTHROMBOCYTOPENIA	298	371,504	371,802
Unspecified thrombocytopenia	FinnGen data D3_THROMBOCYTOPENIANAS	1869	371,504	373,373
Other and unspecified haemorrhagic conditions	FinnGen data D3_HAEMORRHAGICNAS	404	371,504	371,908
Lymphoid leukaemia	FinnGen data CD2_LYMPHOID_LEUKAEMIA_EXALLC	1493	299,952	301,445
Acute lymphocytic leukaemia	FinnGen data C3_ALL_EXALLC	184	287,136	287,320
Chronic lymphocytic leukaemia	FinnGen data C3_CLL_EXALLC	624	287,133	287,757
Myeloid leukaemia	FinnGen data CD2_MYELOID_LEUKAEMIA_EXALLC	674	299,952	300,626

Table 1. continued

Variable	Source	Cases	Controls	Sample size
Acute myeloid leukaemia	FinnGen data C3_AML_EXALLC	231	287,136	287,367
Chronic myeloid leukaemia [CML] BCR/ABL+	FinnGen data CML	232	375,158	375,390
Leukaemia of unspecified cell type	FinnGen data CD2_LEUKAEMIA_NAS_EXALLC	220	299,952	300,172
Myeloproliferative diseases	FinnGen data MYELOPROF_NONCML	1887	375,158	377,045
Polycythaemia vera	FinnGen data POLYCYTVERA	942	286,553	287,495
Chronic myeloproliferative disease	FinnGen data CHRONMYELOPRO	328	375,158	375,486
Essential thrombocythaemia	FinnGen data THROMBOCYTAEMIA	967	286,488	287,455
Eosinophilic disease (BM)	FinnGen data ESOSINOPHIL_DISEASE	398	212,144	212,542
Malignant immunoproliferative diseases	FinnGen data CD2_IMMUNOPROLIFERATIVE_EXALLC	223	299,952	300,175
Diffuse large B-cell lymphoma	FinnGen data C3_DLBCL_EXALLC	1010	287,137	288,147
Follicular lymphoma	FinnGen data CD2_FOLLICULAR_LYMPHOMA_EXALLC	1081	299,952	301,033
Hodgkin lymphoma	FinnGen data CD2_HODGKIN_LYMPHOMA_EXALLC	780	299,952	300,732
Mature T/NK-cell lymphomas	FinnGen data CD2_TNK_LYMPHOMA_EXALLC	335	299,952	300,287
Non-follicular lymphoma	FinnGen data CD2_NONFOLLICULAR_LYMPHOMA_EXALLC	2602	299,952	302,554
Other and unspecified types of non- Hodgkin lymphoma	FinnGen data CD2_NONHODGKIN_NAS_EXALLC	1088	299,952	301,040
Non-Hodgkin lymphoma	FinnGen data C3_NONHODGKIN_EXALLC	928	287,137	288,065
Multiple myeloma and malignant plasma cell neoplasms	FinnGen data CD2_MULTIPLE_MYELOMA_PLASMA_CELL_EXALLC	1249	299,952	301,201
Infectious mononucleosis	FinnGen data AB1_EBV	2353	367,472	369,825
Amyloidosis	FinnGen data E4_AMYLOIDOSIS	413	324,150	324,563
Agranulocytosis	FinnGen data D3_AGRANULOCYTOSIS	3234	370,400	373,634
Drug-induced neutropenia	FinnGen data DRUGADVERS_NEUTROPENIA	1978	375,299	377,277
Eosinophilia	FinnGen data D3_EOSINOPHILIA	182	215,755	215,937
Other and unspecified disorders of white blood cells	FinnGen data D3_WHITEBLOODCELLNAS	1077	370,400	371,477
Other disorders of white blood cells	FinnGen data D3_OTHERWHITECELL	1483	370,400	371,883
Outcome of validation cohort				
Leukaemia	UK Biobank data	1260	372,016	373,276
Lymphoid leukaemia	UK Biobank data	760	372,016	372,776
Myeloid leukaemia	UK Biobank data	462	372,016	372,478
Multiple myeloma	UK Biobank data	601	372,016	372,617
Myeloproliferative neoplasms	PMID: 33057200	1086	407,155	408,241
Lymphomas	UK Biobank data	1752	359,442	361,194

MVMR analysis to adjust and compare the impact of telomere length and the role of epigenetic age acceleration in the risk of these haematological disorders (Supplementary Tables 11 and 12). After adjusting for EAA using the MVMR-IVW method, telomere length was found to be associated with several haematological malignancy outcomes. In the discovery cohort, these outcomes included lymphoid leukaemia (IVW OR 2.8979, 95% CI 1.7986-4.6739, P <0.0001), chronic lymphocytic leukaemia (3.7848, 1.7700-8.1011, 0.0010), acute lymphocytic leukaemia (3.0557, 1.3245-7.0498, 0.0090), essential thrombocythaemia (2.3350, 1.1468-4.7541, 0.0190), malignant immunoproliferative diseases (3.0012)1.0450-8.6379, 0.0410), Hodgkin lymphoma (2.0381, 1.1286-3.6840, 0.0180), non-follicular lymphoma (1.4903, 1.0833-2.0503, 0.0140), other and unspecified types of non-Hodgkin lymphoma (1.8984, 1.1174-3.2252, 0.0180) and non-Hodgkin lymphoma (1.5652, 1.0377-2.3608, 0.0330) (Fig. 1C). However, the significant association observed between telomere length and multiple myeloma and malignant plasma cell neoplasms in the SVMR model was attenuated in the MVMR model and was no longer significant (Fig. 1C). The effects of DNA methylation Hannum age acceleration and DNAm PAI-1 levels that were previously observed in the SVMR for chronic myeloid leukaemia were no longer significant in the MVMR after adjusting for other EAA and telomere length (Fig. 1C). However, in the validation cohort, after adjusting for telomere length and other EAA using MVMR-LASSO regression and MVMR-Egger, genetically predicted Hannum age acceleration remained significantly and positively associated with leukaemia, lymphoid leukaemia, myeloid leukaemia, multiple myeloma (Supplementary Table 13). Significant associations were observed between genetically predicted PhenoAge acceleration and myeloid leukaemia, other disorders of white blood cells, and other and unspecified coagulation defects in the SVMR were attenuated in the MVMR model, and the results were no longer significant (Fig. 1C). Similar results of MVMR analysis were also obtained in the validation cohort (Supplementary Fig. 5).

To prioritize aging-related risk factors for haematological diseases based on our univariable outcomes, we employed a novel multivariable approach, MVMR-BMA. During the model diagnostics, we successfully detected influential and outlying instrumental SNPs (Supplementary Fig. 6). Subsequently, we performed an analysis after eliminating influential and outlying SNPs. Supplementary Table 14 presents the top 10 models ranked by their model PP, along with the MIP and the model-averaged causal effect estimates of the six aging-related factors. Remarkably, the results revealed that telomere length had the strongest association with the five EAA. Notably, analogous results were obtained when all 144 instrumental variables (IVs) were integrated into the analysis (Supplementary Table 15).

Our findings consistently align with results from prospective observational studies, which typically indicate an increased risk of lymphoma, non-Hodgkin lymphoma, and follicular lymphoma in individuals with longer telomeres [8–10]. However, the outcomes of an association cohort study, utilizing data from the UK Biobank, contradict our research findings. This study reveals a significantly higher prevalence of lymphoid and myeloid leukaemia in participants with shorter leukocyte telomere length [11]. These contradictory findings may be attributed to reverse causation in the retrospective studies, stemming from the absence of temporal information. Previous GWAS studies have revealed connections between longer telomeres and specific variations in multiple telomere-related genes such as TERT, TERC, and POT1 [12]. A recently published investigation highlighted that individuals with overly extended telomeres and an inherited ability to elongate telomeres due to POT1 dysfunction are more susceptible to developing lymphoid and myeloid clonal hematopoiesis [13].

The crucial role of epigenetic regulation in the development of haematologic cancers has been underscored by many studies. Our MR estimates for the association between EAA and various forms of leukaemia, namely lymphoid leukaemia, myeloid leukaemia, chronic lymphocytic leukaemia and chronic myeloid leukaemia were broadly consistent with the outcomes reported in the previous studies. For example, Maegawa et al. demonstrate that methylation changes arise as a function of age in normal hematopoiesis and are accelerated in MDS and at the transition from MDS to AML [14]. Nannini et al. discovered significant connections between EAA and the time to relapse among patients with chronic lymphocytic leukaemia [15]. Our study findings suggest that longer telomeres are linked to a higher risk of most haematologic malignancies, but genetically predicted telomere length and EAA do not significantly influence the risk of nearly all benign haematological disorders. This indicates the potential clinical relevance of telomere length, holding promising prospects for clinical implementation.

Yang Li D^{1,2,4}, Jia Chen^{1,2,4}, Ting Sun^{1,2,4}, Yunfei Chen ^{1,2}, Rongfeng Fu^{1,2}, Xiaofan Liu^{1,2}, Feng Xue^{1,2}, Wei Liu^{1,2}, Mankai Ju^{1,2}, Xinyue Dai^{1,2}, Huan Dong^{1,2}, Huiyuan Li^{1,2}, Wentian Wang^{1,2} Ying Chi^{1,2} and Lei Zhang^{1,2,3}

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China. ²Tianjin Institutes of Health Science, Tianjin 301600, China. ³School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China. ⁴These authors contributed equally: Yang Li, Jia Chen, Ting Sun. [⊠]email: zhanglei1@ihcams.ac.cn

DATA AVAILABILITY

All data used in the current study are publicly available GWAS summary data.

CODE AVAILABILITY

For original data and code, please contact zhanglei1@ihcams.ac.cn.

REFERENCES

- 1. Ahmad H, Jahn N, Jaiswal S. Clonal Hematopoiesis and Its Impact on Human Health. Annu Rev Med. 2023;74:249–60.
- Nogueira BMD, Machado CB, Montenegro RC, DE Moraes MEA, Moreira-Nunes CA. Telomere Length and Hematological Disorders: A Review. Vivo. 2020;34:3093–101.
- Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19:371–84.
- Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. The epigenetic clock as a predictor of disease and mortality risk: a systematic review and metaanalysis. Clin Epigenet. 2019;11:62.
- Codd V, Wang Q, Allara E, Musicha C, Kaptoge S, Stoma S, et al. Polygenic basis and biomedical consequences of telomere length variation. Nat Genet. 2021;53:1425–33.
- McCartney DL, Min JL, Richmond RC, Lu AT, Sobczyk MK, Davies G, et al. Genomewide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. Genome Biol. 2021;22:194.
- Kurki MI, Karjalainen J, Palta P, Sipila TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508–18.
- Hosnijeh FS, Matullo G, Russo A, Guarrera S, Modica F, Nieters A, et al. Prediagnostic telomere length and risk of B-cell lymphoma-Results from the EPIC cohort study. Int J Cancer. 2014;135:2910–7.
- Lan Q, Cawthon R, Shen M, Weinstein SJ, Virtamo J, Lim U, et al. A prospective study of telomere length measured by monochrome multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:7429–33.
- Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA. 2010;304:69–75.
- Schneider CV, Schneider KM, Teumer A, Rudolph KL, Hartmann D, Rader DJ, et al. Association of Telomere Length With Risk of Disease and Mortality. JAMA Intern Med. 2022;182:291–300.
- Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet. 2013;45:422–7. 7e1-2
- DeBoy EA, Tassia MG, Schratz KE, Yan SM, Cosner ZL, McNally EJ, et al. Familial Clonal Hematopoiesis in a Long Telomere Syndrome. N. Engl J Med. 2023;388:2422–33.
- Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, et al. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res. 2014;24:580–91.
- Nannini DR, Cortese R, Egwom P, Palaniyandi S, Hildebrandt GC. Time to relapse in chronic lymphocytic leukemia and DNA-methylation-based biological age. Clin Epigenet. 2023;15:81.

AUTHOR CONTRIBUTIONS

YL and LZ designed the study, wrote the first draft of the manuscript. JC and TS conducted statistical analyses and revised the manuscript. RFF, XFL, FX played roles in acquisition of the data and analyses. WL, YFC, MKJ, XYD and HD participated in data interpretation. All authors revised and approved the final manuscript. The guarantor confirms that all listed authors meet the authorship criteria and that no others meeting the criteria have been omitted.

FUNDING

This work was supported by grants from the CAMS Innovation Fund for Medical Sciences (CIFMS) (2022-I2M-2-003, 2023-I2M-QJ-015), National Natural Science Foundation of China (82270152, 81970121, 82100151), National Key Research and Development Program of China (2023YFC2507802), Clinical Research Fund of National Center for Clinical Medical Research of Hematology Diseases (2023NCRCA0109).

COMPETING INTERESTS

The authors declare no competing interests.

ETHICS APPROVAL

This study utilized publicly available data from participant studies that had already received ethical approval from a committee responsible for human experimentation. No additional ethical approval was necessary for this particular study.

6

Correspondence

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41408-024-01035-5.

Correspondence and requests for materials should be addressed to Lei Zhang.

Reprints and permission information is available at http://www.nature.com/ reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by/4.0/.

© The Author(s) 2024